Hot Products
| Catalog No. | Information |
| CFN91028 | Daidzin 6''-O-malonate Daidzin 6''-O-malonate may have anticancer activity. |
| CFN89161 | Dalbergin Dalbergin exhibits similar bone conserving effect against bone-loss as estradiol treatment, it as a therapeutic candidate against postmenopausal osteoporosis. Dalbergin also prevents some effects of photoaging and maintain skin integrity by regulating the degradation of the extracellular matrix proteins. |
| CFN98874 | Dammaradienyl acetate Reference standards. |
| CFN99476 | Dammarenediol II Dammarenediol II may have the ability to prevent diabetic microvascular complications, including diabetic retinopathy, it can inhibit vascular endothelial growth factor (VEGF)-induced intracellular reactive oxygen species generation and stress fiber formation and vascular endothelial-cadherin disruption. The medicinally important dammarenediol II can be ectopically produced in tobacco, and the production of dammarenediol-II in tobacco plants allows them to adopt a viral defense system. |
| CFN98723 | Damnacanthal Damnacanthal possesses anti-cancer, immunomodulatory, antinociceptive and anti-inflammatory actions, it can treat or prevent hepatocellular carcinoma through its inhibitory effects on the HGF/c-Met axis. Damnacanthal inhibits mast cell activation induced by different stimuli and open a new window for the use of this compound as a mast cell stabilizer. Damnacanthal can inhibit the NF-κB/receptor-interacting protein-2/caspase-1 signal pathway by inhibiting p56lck tyrosine kinase. |
| CFN91838 | Damulin A Damulin A and Damulin B as potential activators of AMP-activated protein kinase (AMPK) from Gynostemma pentaphyllum, which may contribute to beneficial effect of G. pentaphyllum on glucose and lipid metabolism. |
| CFN91837 | Damulin B Damulin A and Damulin B as potential activators of AMP-activated protein kinase (AMPK) from Gynostemma pentaphyllum, which may contribute to beneficial effect of G. pentaphyllum on glucose and lipid metabolism. |
| CFN92167 | Danshenol A Danshenol A has strong aldose reductase (AR) inhibitory activity, has IC50 of 0.10 microM which is comparable to that of epalrestat in clinical use. Danshenol A also has antitumor activity in T-24, QGY, K562, Me180 and BIU87 cell lines, shows inhibited growth of K562 (IC50 = 0.53 μg/mL), T-24 (IC50 = 7.94 μg/mL), QGY (IC50 = 4.65 μg/mL) and Me180 (IC50 = 6.89 μg/mL) cell lines. |
| CFN90474 | Danshenol B Danshenol B has aldose reductase(AR) inhibitory activity. |
| CFN99539 | Danshensu Danshensu has anxiolytic-like, cardioprotective, neuroprotective, and antioxidant activities. It can enhance HO-1 expression to suppress 6-OHDA-induced oxidative damage via PI3K/Akt/Nrf2 signaling pathways and can reduce 6-OHDA-induced dopaminergic neuronal loss in zebrafish. Chronic treatment with danshensu can prevent/attenuate the formation of atherosclerosis. |
